



PHYLOGICA

BREAKTHROUGH PEPTIDE THERAPEUTICS

CHAIRMAN APPOINTMENT

Perth, Australia 8 October 2015: Phylogica Ltd (ASX:PYC, XETRA:PH7)

Directors have appointed existing Director Mr Bruce McHarrie as Chairman of the board.

The outgoing chairman Dr Doug Wilson remains on the board as a Non-executive Director and will assume additional duties in the Company's drug development program. Phylogica is grateful for the dedicated service Dr Wilson has provided the Company in his role as Chairman where he led a critical stage in the Company's development.

In the recent shareholder update the Company alluded to a recent strategic review as the focus of its business shifts from early drug discovery to product development, with the objective of creating Phylogica's own therapeutic compounds.

Management is now intensely focused on drug development and Dr Wilson will take a more direct role by virtue of his decades of experience in drug development for large pharmaceutical companies.

Mr McHarrie is a founding Director of Phylogica and was formerly with the Telethon Kids Institute where his roles included Chief Financial Officer, Director of Operations and Director of Strategic Projects. The Institute vended its Phylomer technology into the Company for its subsequent ASX listing mid-2005.

Prior to joining the Institute Mr McHarrie was with the London-based Bioscience Unit at Rothschild Asset Management, a private equity company investing in early stage biotechnology/healthcare companies. He is now consulting, principally in the health and life sciences sectors, and is also a director of recently listed Adherium Limited.

For further information, please contact:

Dr Richard Hopkins

Tel: +61 8 9489 7855

Email: richardh@phylogica.com

Rudi Michelson

Monsoon Communications

Tel: + 61 3 9620 3333

Email: rudim@monsoon.com.au

About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics from the most structurally diverse libraries available. The Company listed on the ASX in

2005 as a spin out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company's drug discovery platform is based on its proprietary Phylomer® libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to adopt stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer® libraries and proprietary screening technologies in exchange for licence fees, milestones and royalties. Partners from discovery alliances within the last 5 years include Roche, MedImmune, Pfizer, Janssen, Cubist Pharmaceuticals and Genentech.

About Phylomer® Peptides

Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly, and specifically to disease associated target proteins, both inside and outside cells. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases, such as infectious diseases, cancer, autoimmunity and heart disease. Phylomer peptides can have drug-like properties, including specificity, potency and thermal stability, and are capable of being produced by synthetic or recombinant manufacturing processes. Phylomer peptides are also readily formulated for administration by a number of means, including parenteral or intranasal delivery approaches. Current Phylomer libraries comprise more than 400 billion distinct sequences derived from thousands of protein structure families encoded by biodiverse genomes, representing the most structurally diverse peptide libraries available. Phylomer peptides have also been demonstrated to have world-class cell penetrating ability, enabling them to deliver protein cargoes with unprecedented efficiency.